<i>Lactobacillus reuteri</i> DSM 17938 in the Treatment of Functional Abdominal Pain in Children

Jadrešin, Oleg; Hojsak, Iva; Mišak, Zrinjka; Kekez, Alemka Jaklin; Trbojević, Tena; Ivković, L; Kolaček, Sanja

doi:10.1097/mpg.0000000000001478

Cited by 58 publications

(59 citation statements)

References 52 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Indeed, Lactobacillus species are often reported as beneficial for abdominal pain in functional GI disorders. 63,64 Although the exact mechanism of pain in IBS is as yet unclear, it is possible this symptom is mediated via persistent low-grade intestinal inflammation and changes in the quantity of gut microbiota. 65 Overall, the act of altering the gut microbiota via the administration of probiotics seems to yield beneficial results for general IBS symptoms.…”

Section: Discussionmentioning

confidence: 99%

Efficacy and Safety of Probiotics, Prebiotics and Synbiotics in the Treatment of Irritable Bowel Syndrome: A systematic review and meta-analysis

Asha¹,

Khalil

2020

Sultan Qaboos Univ Med J

View full text Add to dashboard Cite

Treatments that target alterations in gut microbiota may be beneficial for patients with irritable bowel syndrome (IBS). A systematic review and meta-analysis was conducted of randomised clinical trials (RCTs) evaluating the efficacy and safety of probiotics, prebiotics and synbiotics. Factors considered in the analysis included global IBS symptoms and/or abdominal pain, secondary symptoms and the frequency of adverse events. A total of 33 RCTs involving 4,321 patients were identified. Overall, probiotics significantly improved global IBS symptoms compared to placebos (standardised mean difference = −0.32, 95% confidence interval: −0.48 to −0.15; P <0.001), with significant heterogeneity between studies (I2 = 72%; P <0.001). This remained apparent in both single- and multi-strain probiotic interventions as well as synbiotic formulations. However, evidence regarding prebiotics was scarce. There were no significant inter-group differences in terms of the frequency of adverse events. Future RCTs should address methodological limitations, including short follow-up periods and patient adherence.Keywords: Irritable Bowel Syndrome; Gastrointestinal Microbiome; Dietary Supplements; Probiotics; Prebiotics; Synbiotics; Meta-Analysis; Systematic Review.

show abstract

Section: Discussionmentioning

confidence: 99%

Efficacy and Safety of Probiotics, Prebiotics and Synbiotics in the Treatment of Irritable Bowel Syndrome: A systematic review and meta-analysis

Asha¹,

Khalil

2020

Sultan Qaboos Univ Med J

View full text Add to dashboard Cite

show abstract

“…While its ability to decrease the intestinal pH to a level unfavorable to most pathogenic bacteria, placebo‐controlled studies show that L reuteri supplementation provides only a marginal improvement in IBS‐related symptoms. L reuteri (See Table )…”

Section: Probioticsmentioning

confidence: 99%

“…L reuteri 41,42 (See Table 2) 3.3 | Saccharomyces Improvement in abdominal pain/discomfort has been reported in Saccharomyces (S) cerevisiae and S boulardi yeast strains in IBS patients. 43,44 S cerevisiae has been shown in IBS patients to improve bloating and abdominal pain/discomfort after 4 weeks of treatment.…”

Section: Lactobacillusmentioning

confidence: 99%

Targeting the gut microbiota for the treatment of irritable bowel syndrome

Herndon

Wang

2019

The Kaohsiung J of Med Scie

View full text Add to dashboard Cite

Irritable bowel syndrome (IBS) is a chronic gastrointestinal disorder that affects an estimated 11% of people across the world. IBS patients are one of the largest subgroups seen in gastroenterology clinics, exhibit a lesser quality of life, and take greater use of the healthcare system. The exact etiology of IBS remains uncertain. Alterations in the gut microbiome may characterize apotential mechanism in the pathogenesis of IBS. This hypothesis is paralleled by rodent models in which manipulation of the gut microbiota leads to disturbed physiological functions along the brain‐gut axis. Recent research in IBS treatments has redirected its focus towards gu microbiome based therapeutics. In this review, we discuss potential roles of enteric bacteria in the pathogenesis of IBS and its comorbidities. We then explore the manipulation of the enteric microbiota by prebiotics, probiotics, antibiotics, dietary changes, and fecal microbiota transfer. We also discuss the positive and negative effects of these therapeutics on IBS symptoms.

show abstract

“…Studies have indicated positive therapeutic effects of probiotics, including in irritable bowel syndrome (IBS) (Ford, Harris, Lacy, Quigley, & Moayyedi, ), obesity (Emond, Golding, & Peckham, ), autism spectrum disorders (ASDs) (Grimaldi et al, ), diabetes mellitus (Balakumar et al, ), asthma (Fonseca et al, ), and cognitive and emotional impairments in fibromyalgia (Roman et al, ). In addition, increasing evidence has shown that the gut microbiota dramatically impacts visceral pain (Luczynski et al, ; Perez‐Burgos et al, ; SM, Dinan, & Cryan, ), functional abdominal pain (FAP) (Jadresin et al, ), chronic prostatitis/chronic pelvic pain syndrome (Shoskes et al, ), inflammatory pain induced by formaldehyde (Amaral et al, ), and chemotherapy‐induced pain (Shen et al, ). However, few studies have focused on the relationship between probiotics and neuropathic and inflammatory pain.…”

Section: Introductionmentioning

confidence: 99%

Oral Lactobacillus reuteri LR06 or Bifidobacterium BL5b supplement do not produce analgesic effects on neuropathic and inflammatory pain in rats

et al. 2019

View full text Add to dashboard Cite

Background Previous studies have reported that certain bacteria exert visceral antinociceptive activity in visceral pain and may also help to relieve neuropathic and inflammatory pain. Objective: The aim of this study was to explore the analgesic effect of Lactobacillus reuteri LR06 (LR06) or Bifidobacterium BL5b (BL5b) in chronic pain in vivo. Design Rats were randomly assigned into four groups: sham, Chronic Constriction Injury (CCI)/Complete Freund's Adjuvant (CFA) + control, CCI/CFA + LR06, and CCI/CFA + BL5b. Rats from the probiotic groups were treated with 1 x 109 cfu (LR06 or BL5b) daily through gavage for 14 days after a pain model was successfully established. Mechanical and thermal hyperalgesia were used to assess the analgesic effect of the probiotics. Iba1 was used to verify the microglial inflammatory reaction in the different groups. Results The results showed that probiotics L. reuteri LR06 or Bifidobacterium BL5b had no significant antinociception effects in chronic pain rats. The chronic pain‐induced activation of microglia (Iba1) was not relieved by probiotics in CCI/CFA‐induced neuropathic or inflammatory pain rats. Conclusion Our results suggested that L. reuteri LR06 or Bifidobacterium BL5b had no antinociceptive effects on CCI‐induced neuropathic pain and CFA‐induced inflammatory pain in rats.

show abstract

Lactobacillus reuteri DSM 17938 in the Treatment of Functional Abdominal Pain in Children

Abstract: Administration of L reuteri DSM 17938 was associated with a possible reduction of the intensity of pain and significantly more days without pain in children with FAP and IBS.

Cited by 58 publications

References 52 publications

Efficacy and Safety of Probiotics, Prebiotics and Synbiotics in the Treatment of Irritable Bowel Syndrome: A systematic review and meta-analysis

Efficacy and Safety of Probiotics, Prebiotics and Synbiotics in the Treatment of Irritable Bowel Syndrome: A systematic review and meta-analysis

Targeting the gut microbiota for the treatment of irritable bowel syndrome

Oral Lactobacillus reuteri LR06 or Bifidobacterium BL5b supplement do not produce analgesic effects on neuropathic and inflammatory pain in rats

Contact Info

Product

Resources

About